| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.038 | 0.4 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.4 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.14 | 0.4 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |